Active Ingredient(s): Iobenguane I 131
FDA Approved: * July 30, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Azedra Overview

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter, typically used as a radiopharmaceutical.[1] It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments. It localizes to adrenergic tissue and thus can be used to identify the location of tumors such as pheochromocytomas and neuroblastomas.[2] ...

Read more Azedra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Azedra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Iobenguane I 131
  • Injection: 555mbq/ml(15mci/ml), 5ml
  • Solution: 10mci/5ml (2mci/ml), 15mci/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Azedra: (1 result)

Sorted by National Drug Code
  • 71258-015 Azedra 15 mci/Ml Intravenous Injection, Solution by Progenics Pharmaceuticals, Inc.

Other drugs which contain Iobenguane I 131 or a similar ingredient: (2 results)